Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 24;7(6):94.
doi: 10.3390/mi7060094.

The GenePOC Platform, a Rational Solution for Extreme Point-of-Care Testing

Luc Bissonnette  1   2 , Michel G Bergeron  3   4
Affiliations
Review

The GenePOC Platform, a Rational Solution for Extreme Point-of-Care Testing

Luc Bissonnette et al. Micromachines (Basel). .

Abstract

Extreme point-of-care (POC) testing for infections, as performed (endured) in low-resource settings, developing countries, tropical areas, or in conditions following emergency crises or natural disasters, must be undertaken under environmental, logistic, and societal conditions which impose a significant deal of stress on local human populations and healthcare providers. For disease diagnostics or management, simple and robust biomedical equipment and reagents are required and needed. This chapter aims to overview some of these stresses (requirements) and intends to describe some of the solutions already engineered at the heart of centripetal (centrifugal) microfluidic platforms such as that of GenePOC Inc. to enable rapid, robust, and reproducible nucleic acid-based diagnostics of infectious diseases, to better control the morbidity and mortality of infections and the expanding threat posed by antimicrobial resistance.

Keywords: GenePOC; centripetal (centrifugal) microfluidics; disasters; emergencies; extreme point-of-care testing; infectious disease diagnostics; isothermal amplification; low-resource settings; polymerase chain reaction.

PubMed Disclaimer

Conflict of interest statement

Luc Bissonnette declares having no conflict of interest, while Michel G. Bergeron is the founder of GenePOC Inc. of Québec City, QC, Canada.

Figures

Figure 1
Figure 1
Schematic description of the GenePOC disposable, a MCD integrating the essential functions and components for performing nucleic acid-based diagnostics at POC. Copyright © GenePOC Inc. 2016 All rights reserved.
Figure 2
Figure 2
The workflow of the GenePOC platform. Source: GenePOC Inc.
See this image and copyright information in PMC

References

    1. Pant Pai N., Vadnais C., Denkinger C., Engel N., Pai M. Point-of-care testing for infectious diseases: Diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012;9:e1001306. - PMC - PubMed
    1. Schito M., Peter T.F., Cavanaugh S., Piatek A.S., Young G.J., Alexander H., Coggin W., Domingo G.J., Ellenberger D., Ermantraut E., et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J. Infect. Dis. 2012;205:S169–S180. doi: 10.1093/infdis/jis044. - DOI - PMC - PubMed
    1. Zwerling A., Dowdy D. Economic evaluations of point of care testing strategies for active tuberculosis. Expert Rev. Pharmacoecon. Outcomes Res. 2013;13:313–325. doi: 10.1586/erp.13.27. - DOI - PubMed
    1. Bissonnette L., Chapdelaine S., Peytavi R., Huletsky A., Stewart G., Boissinot M., Allibert P., Bergeron M.G. A revolutionary microfluidic stand-alone platform (GenePOC) for nucleic-acid based point-of-care diagnostics. In: Kost G.J., Corbin C.M., editors. Global Point of Care—Strategies for Disasters, Emergencies, and Public Health Resilience. AACC Press; Washington, DC, USA: 2015. pp. 235–247.
    1. Pai M., Ghiasi M., Pant Pai N. Point-of-Care diagnostic testing in global health: What is the point? Microbe. 2015;10:103–107. doi: 10.1128/microbe.10.103.1. - DOI

LinkOut - more resources